Pharma companies have been part of the global economy and our health systems for centuries. | Pharma companies have been part ...

Four years after Spero Therapeutics received a complete response letter from the FDA, rejecting its oral treatment for ...

After disclosing a security breach last week concerning “a limited number of internal IT systems,” details on the cyber ...

With an increasingly promising roster of approved cell therapies still burdened by complex manufacturing, multiple companies ...

As it prepares to launch up to three new products from 2027 through 2028, Moderna is adjusting its way of doing business.  | ...

Before Indian drugmaker Aurobindo can complete its acquisition of Pennsylvania generics specialist Lannet, it will have to ...

In another Novo Nordisk manufacturing update, the company announced locally that it will invest 200 million yuan ($29 million ...

With pharma and life sciences deal values surpassing $65 billion in Q1, marking the strongest quarter in the industry since ...

With good-but-not-great updated data on its approved oncology combo of avutometinib plus defactinib (A+D) in first-line ...

While patients in Novo trials don't need to take any action, the company recommends patients "remain vigilant and report to ...

Merck & Co.’s first-in-class HIF-2 alpha inhibitor Welireg is touching down in the clear cell renal cell carcinoma (ccRCC) | ...

Following another phase 3 failure for Gilead Sciences’ Trodelvy, the race to bring a TROP2 antibody-drug conjugate (ADC) to ...